Your browser doesn't support javascript.
loading
Genetic complexity impacts the clinical outcome of follicular lymphoma patients.
García-Álvarez, María; Alonso-Álvarez, Sara; Prieto-Conde, Isabel; Jiménez, Cristina; Sarasquete, M Eugenia; Chillón, M Carmen; Medina, Alejandro; Balanzategui, Ana; Maldonado, Rebeca; Antón, Alicia; Rodríguez, Marta; Blanco, Oscar; Díaz, Luis G; Tamayo, Pilar; Blanco, Pedro; Esteban, Carmen; González-Calle, Verónica; Puig, Noemí; Gutiérrez, Norma; Martín, Alejandro; García-Sanz, Ramón; González, Marcos; Caballero, M Dolores; Alcoceba, Miguel.
Afiliação
  • García-Álvarez M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Alonso-Álvarez S; Department of Hematology, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
  • Prieto-Conde I; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Jiménez C; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Sarasquete ME; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Chillón MC; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Medina A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Balanzategui A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Maldonado R; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Antón A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Rodríguez M; Department of Pathology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Blanco O; Department of Pathology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Díaz LG; Department of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Tamayo P; Department of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Blanco P; Department of Otorhinolaryngology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Esteban C; Department of General and Gastrointestinal Surgery, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • González-Calle V; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Puig N; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Gutiérrez N; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Martín A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • García-Sanz R; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain. rgarcias@usal.es.
  • González M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Caballero MD; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Alcoceba M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Blood Cancer J ; 11(1): 11, 2021 01 11.
Article em En | MEDLINE | ID: mdl-33431798
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article